INTRODUCTION
Milk or colostrum can support the serum-free proliferation ofmammalian cells (Klagsbrun, 1978 (Klagsbrun, , 1980 Carpenter, 1980; Steimer & Klagsbrun, 1981; Sereni & Baserga, 1981; Brown & Blakely, 1983; Read et al., 1984) . The active components are low-Mr acid-stable proteins that occur at especially high concentrations in colostrum (Klagsbrun, 1978 (Klagsbrun, , 1980 Brown & Blakely, 1983) . Further characterization has identified: (a) epidermal growth factor as the major growth-promoting agent in human milk, at least for fibroblasts (Carpenter, 1980; Shing & Klagsbrun, 1984) ; (b) insulin in bovine colostrum as the key growth factor for H35 and MHlC1 hepatoma cells ; and (c) plateletderived growth factor or a closely related protein as an important mitogen in goat colostrum (Brown & Blakely, 1984) . Insulin-like growth factor-I (IGF-1) is also present at significant concentrations in human milk (Baxter et al., 1984) .
In a wide range of normal and transformed cells, bovine colostrum potently stimulates protein synthesis and inhibits protein breakdown, dual anabolic responses associated with the stimulation of cell growth (Ballard, 1982; Ballard et al., 1982) . The effects cannot be attributed to insulin or epidermal growth factor, because most of the cell lines tested do not respond to either growth factor at the low concentrations present in bovine colostrum Gunn et al., 1983; Read et al., 1984) . Since the identity of the major growthpromoting activity was not known, we elected to use one of these non-selective assays, the stimulation of protein synthesis (Read et al., 1984) , for screening purposes during the purification. The studies reported herein have resulted in the purification and characterization of IGF-1 from bovine colostrum. 150 mM-NaCl and 0.1 % bovine serum albumin, which was Cohn fraction V previously treated as described by Chen (1967) ]. After incubation as described above for a further 17 h, the monolayers were washed at 0°C, twice with Hanks' salts, twice with 5% trichloroacetic acid over a 10 min period, and once with water before dissolution in 0.5 M-NaOH containing 0.1 % Triton X-100. Radio , and for the competitive binding with '251-labelled bovine IGF-I to human placental membranes in the first of the two following papers Proteins were sequenced by using the Applied Biosystems model 470A gas-phase sequencer and the procedures given by the manufacturers and described by Hunkapiller et al. (1983) . For some analyses the proteins were S-carboxymethylated before sequencing. This was accomplished by dissolving freeze-dried protein in 50 #1 of 10 mM-HCl and adding 100 ,gl of 6 M-guanidinium chloride in 0.1 M-Tris at pH 7.3, followed by 1O #1 of 0.1 M-dithiothreitol. The solution was then incubated at 85°C for 10 min, cooled to 20°C, and 30 ,u of 0.25 M-sodium iodoacetate in the above guanidinium chloride/Tris buffer added. After the solution had been left in the dark for 2 h, 10 l1 of trifluoroacetic acid was added and the solution applied to a 2.1 mm x 30 mm C18 column equilibrated with 0.1 % trifluoroacetic acid and eluted with a 0-60% (v/v) acetonitrile gradient in 0.1 % trifluoroacetic acid. The reduced and carboxymethylated protein was detected by A215 (Hunkapiller et al., 1983) .
M, measurements
Each protein sample dissolved in 40% (v/v) acetonitrile in 0.1 % trifluoroacetic acid was applied in a volume of 150 c1 to a TSK G3000 SW column (LKB) of dimensions 7.5 mm x 600 mm, equipped with a 7.5 mm x 75 mm guard column and equilibrated with the same solution. The flow rate was 0.4 ml/min, with absorbance measured at 210 nm. If required, 0.4 ml fractions were collected for measurement of growth-factor activity.
RESULTS
The purification described below is that carried out with a single batch of colostrum collected from cow Al. Acid extraction Approx. 2.5 litres of colostrum were centrifuged at 20000 g for 30 min at 5 'C. The infranatant (2.3 litres) was adjusted to pH 2.8 with acetic acid over a period of 1 h while it was stirred vigorously at 2 'C. Stirring was continued overnight at 2 'C, during which the viscous mixture became considerably more fluid. Centrifugation at 20000 g for 30 min at 5 'C yielded an opalescent extract (1.5 litres). Extraction of the large amount of pelleted protein with 1 M-acetic acid, although yielding additional growth-promoting material, was not routinely adopted because the specific bioactivity in the second extract was substantially lower than in the primary extract. In most purifications the primary acid extract resulted in the recovery of 60-80% of the bioactivity accompanied by removal of 90-95% of the protein.
However, in the example given in Table 1 , the bioactivity recovered was apparently very low and is not reported in Table 1 . Presumably this situation was an artefact of loss of material in the sample taken for dialysis and assay, because later steps in the purification indicated amounts of bioactivity that were typical of other purifications. Chromatography on SP-Sephadex A 100 g portion of SP-Sephadex C-25 was hydrated with water at 95 'C for 2 h and converted into the hydrogen form by treatment with acetic acid at pH 2.5. The pH 2.8 colostrum extract was added to the gel layer and the mixture stirred overnight at 2 'C. The slurry was poured into a Pharmacia K50 column (5 cm diameter) at 2°C, allowed to settle for 20 min and packed at a flow rate of 8 ml/min. The gel bed was washed with 0.5 litre of I M-acetic acid and subsequently with 50 mm-ammonium acetate, pH 5.5, at a flow rate of 4 ml/min until the A280 (5 mm light path) was below 0.05. For the purification in Table 1 this required 6.6 litres of pH 5.5 buffer.
Elution ofbioactivity was achieved with a 500 ml linear gradient from the pH 5.5 buffer to 0.25 M-NH3 containing 0.5 M-NaCl, followed by a further 3.75 litres of the latter solution. The volume of eluate obtained with significant absorbance at 280 nm was 3.95 litres. Although this step typically results in an increase in specific activity of 5-7-fold and a yield of 50-70%, the illustrated example ofcolostrum Al purification (Table 1) This and all subsequent steps were carried out at 22 'C. The eluate from SP-Sephadex chromatography was adjusted to 0.1 % with trifluoroacetic acid and the pH to 2.1 with concentrated HCI. This mixture was stirred for 15 h and the fine precipitate removed by centrifugation at 20000 g for 30 min. The supernatant was pumped through a series of ten Sep-Pak cartridges previously equilibrated with 0.1 % trifluoroacetic acid by using a flow rate of 1 ml/min. The cartridge series was washed with 0.1 % trifluoroacetic acid and eluted with 50% (v/v) of acetonitrile in 0.1 % trifluoroacetic acid. The eluate (20 ml) retained 33 % of the bioactivity in the starting colostrum ( Fig. 1) , together with 950 mg of protein, and represented a cumulative purification of 100-fold (Table  1 ). An additional 10-15% of the total colostrum bioactivity could be recovered from the solution passed through the Sep-Pak cartridges by passage through, and elution from, a further series of cartridges. This rechromatography was not used in the protocol shown in Table 1 Fig. 2(a) A second attempt to account for the low recovery in fractions [14] [15] [16] involved the addition of portions of this pool to equal volumes of other fractions. Bioactivity measurements gave results commensurate with the sum of each activity, except for fractions 69-87. When material from these fractions was added to an amount of the fraction 14-16 pool that itself produced only a small increase in protein synthesis, the resultant bioactivity was substantially higher than expected. Presumably this result reflects a synergistic stimulation of protein synthesis by one or more components in fractions 69-87 acting with the active substance in fractions 14-16.
The third test of recovery involved a radioreceptor assay using 125I-labelled IGF-1 prepared from the final purification step (see below). Portions of the sample loaded on to the first h.p.l.c. column and the combined fractions 14-16 were freeze-dried, dissolved as above and added to human placental membranes, together with labelled IGF-1. Binding of radioactivity was measured over a wide concentration range, as described in the following paper . Parallel competition curves showed that the 31.5 ml loaded on to the h.p.l.c. column contained 2.54 mg of bovine IGF, whereas 1.31 mg or 52% was recovered in fractions 14-16. This and the previous two experiments show that the low recovery of bioactivity in the peak fractions is not associated with comparable losses of IGF, but rather is consistent with the separation of bioactivity into forms that act synergistically. Second h.p.l.c. step
The pool of fractions 14-16 (5.5 ml) was diluted with 2 ml of 0.1 % trifluoroacetic acid, and 5.7 ml was injected on to the same C18 column that was used for the first h.p.l.c. step, except that it had previously been equilibrated with 30.8% (v/v) acetonitrile in 0.1 % trifluoroacetic acid. The flow rate was 1 ml/min during loading and 0.5 ml/min during elution. A linear gradient to 42.80% (v/v) acetonitrile in 0.10% trifluoroacetic acid was applied over 160 min, and the absorbance measured at 280 nm (Fig. 2b) . Most of the bioactivity eluted at an acetonitrile concentration of 34.5%, with a further small peak at 360%. The bioactivity in the second peak, although also seen during the purification of growth factors from other batches of colostrum, has not been further investigated, nor has it been taken into account in the calculations of recovered activity. The second h.p.l.c. produced a 3-4-fold increase in specific activity and a recovery of 700% (Fig. 1, Table 1 ).
Third h.p.l.c. step The pooled fractions (35-37, 3.0 ml) were diluted with 1.5 ml of 0.100 trifluoroacetic acid, and 4 ml was applied to an LKB LiChrosorb C18 column (5 ,tm particle size; 4 mm x 250 mm) previously equilibrated with 10% (v/v) propan-1-ol in 0.1 % trifluoroacetic acid. The elution program at a flow rate of 0.5 ml/min involved a 7 min linear gradient to 17% (v/v) propan-l-ol followed by a 28 min linear gradient to 18.4% (v/v) propan-l-ol, an 85 min linear gradient to 20.5% (v/v) propan-1-ol and, finally, a 45 min gradient to 45% (v/v) propan-1-ol. The trifluoroacetic acid concentration was 0.1 % throughout.
The eluate was monitored at 280 nm (Fig. 3a) profile. Fractions 22-24 (3 ml) contained 70% of the applied bioactivity and represented a 4.7-fold purification (see Fig. 1, Table 1 ).
Fourth h.p.l.c. step
The pooled fractions were diluted to 4.3 ml with 1.3 ml of0.13% heptafluorobutyric acid and 4.1 ml was injected on to the same column used for the third h.p.l.c. step, but equilibrated with 10% (v/v) propan-l-ol in 0.13% heptafluorobutyric acid. The flow rate during elution was 0.5 ml/min and the program included a 29 min linear gradient to 29.6% (v/v) propan-l-ol followed by a 119 min linear gradient to 41.5% (v/v) propan-l-ol with the counter-ion maintained at 0.13%. The absorbance was monitored at 280 nm, and portions of each fraction freeze-dried for bioassay and radioreceptor assays (Fig.  3b) . The protein-synthesis bioassay showed a broad region of activity from fractions 41 to 50, with peaks apparently at fractions 43 and 47. It should be stressed that the assay performed in this manner when only a single volume from each fraction tested is only semi-quantitative.
A radioreceptor assay with 125I-labelled bovine IGF-l using human placental membranes demonstrated a peak of activity in fraction 47, but again the activity was distributed over ten fractions (Fig. 3b) . The pattern was very similar when fractions were screened by using a radioreceptor assay that measured competition with 1251-labelled rIGF-2 binding to L6 myoblasts (Fig. 3b) .
On the basis of the three measurements, the active fractions were combined into pool 1 (fractions 41-43), pool 2 (fractions 44 and 45) and pool 3 (fractions 46-49). The bioactivity in each of these pools was measured over a wide concentration range and is given in Table 1 . The resultant curve for pool 3 is shown in Fig. 1 and indicates a 2.9-fold purification over the material loaded on to the fourth h.p.l.c. column. The corresponding purification factor for pool 2 is 2.7-fold. Amino acid sequence of bovine growth factor The sequence of the purified growth factor after S-carboxymethylation has been determined between the N-terminus and residue 30: 10 Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val- Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-
30
Phe-Asn-Lys-Pro-Thr-GlyComparison of these results with the reported sequences for human IGF-1 (Rinderknecht & Humbel, 1978) and rat IGF-1 (Rubin et al., 1982) indicates no differences between the three growth factors. Clearly, the purified growth factor is bovine IGF-1.
Mr determination
The Mr of the growth factor was estimated by gel-permeation chromatography of a sample from a different purification (A2) from that reported in Table 1 (Fig. 4) . A peak of material absorbing at 210 nm was detected at a mean elution volume of 17.9 ml, giving Mr of 7800 by reference to the elution volumes of ribonuclease A, lima-bean (Phaseolus limensis) trypsin inhibit, t mo-iise epidermal growth factor, insulin and insulin B chain (Fig. 4) . The absorbing material was essentially pure, as evidenced by peak shape. Moreover, bioactivity measurements confirmed that the growth factor was eluted at the same time as the peak absorbance. A comparable analysis of pool 3 from the purification described in Table 1 gave a similar Mr but with approx. 20% of the 210 nmabsorbing material appearing as shoulders before and after the major peak.
DISCUSSION
The major growth factor in bovine colostrum, assessed by its ability to stimulate protein synthesis in rat L6 myoblasts, has been purified to near homogeneity and identified by partial sequence analysis as IGF-1. Our initial attempts at purification utilized Sephadex G-100 chromatography under acid conditions as the first step Read et al., 1983) . This procedure had the advantage that the growth-promoting activity was separated from a high-Mr component that bound the bioactivity at neutral pH, but the disadvantage of being slow and unsuitable for large-scale application. Nevertheless, Mr fractionation in acid was required to remove binding protein, a situation comparable with that found for IGF in serum (Rinderknecht & Humbel, 1976; Rubin et al., 1982) . The acid-extraction method finally adopted as the first step in the purification of the bovine growth factor gave satisfactory enrichment ofbioactivity and was suitable for the processing of several litres of colostrum.
After absorption of the extracted bioactivity to SP-Sephadex, elution was accomplished by a combination of high salt and very high pH, but, even under such conditions, the bioactivity was eluted in an extremely broad peak. Although gradual desorption may reflect the presence of several growth factors, each with a different alkaline pl, an additional explanation is that the growth factor is poorly soluble in aqueous solutions at neutral and alkaline pH. Indeed, bioactivity can be precipitated at later stages in the purification procedure by neutralizing the acid solutions used as h.p.l.c. solvents. This insolubility of the bioactivity contrasts with reports of the purification of human IGF-1 (Svoboda et al., 1980) , as well as rat IGF-1 and IGF-2 (Moses et al., 1980; Marquardt et al., 1981; Rubin et al., 1982) . In each of the above protocols, satisfactory separation was achieved on isoelectric-focusing gels. However, we found that the bovine bioactivity did not migrate on isoelectric-focusing gels above pH 4, owing to precipitation, unless high concentrations of urea were present. This property also applied to the purified bovine IGF-1. Since we found very poor recovery of bioactivity in steps subsequent to isoelectric focusing in urea, the technique could not be used for the purification of bovine IGF. As yet we have no explanation for the low relative solubility of the bovine form of IGF-I at neutral or alkaline pH.
We have noted some variability in the elution pattern of bioactivity at the fourth h.p.l.c. step. Whereas for the purification illustrated in Fig. 3(b) the highest specific activity occurred in pool 3 and the lowest in pool 1, other purifications produced much higher specific activities for protein eluted at the same propan-l-ol concentration as pool 1. It seems unlikely that the broad region of bioactivity including pools 1, 2 and 3 reflects a variable proportion of IGF-2 at the fourth h.p.l.c. step, because the bioactivity pattern matches well with both the radioreceptor assay using human placental membranes and labelled IGF-1 as the radioligand and the radioreceptor assay with L6 myoblasts and IGF-2 as radioligand (Fig. 3b) . These measurements are selective respectively for IGF-1 and IGF-2 [see the accompanying papers Ballard et al., 1986) ], so that a significant amount of IGF-2 in one pool of the preparation would be readily detected. Moreover, isoelectric focusing of iodinated h.p.l.c.-step 4 material in the presence of urea gave no evidence of radioactive bands at the neutral pH expected for IGF-2 (results not shown).
A more likely explanation of the distribution of bioactivity between peaks 1, 2 and 3 is that two or more variants of IGF-1 are present. Partial sequence analysis has been carried out on material that is eluted at the same position as pool 1, but with a specific bioactivity equivalent to pool 3 in the purification summarized in Table 1 . As indicated in the Results section, an N-terminal sequence identical with that of human IGF-1 was obtained (Rinderknecht & Humbel, 1978; Klapper et al., 1983) . The actual pool-3 sample from the protocol in Table 1 had the same N-terminal sequence, except for the omission of the N-terminal tripeptide Gly-Pro-Glu. Indeed, in another purification, where protein eluted in the regions of pool 1 and pool 3 had similar bioactivities, the pool-I protein sequenced as complete IGF-1, whereas the pool-3 protein again lacked the N-terminal tripeptide. We conclude, therefore, that the broad region of bioactivity from pool 1 and pool 3 contained complete IGF-1 together with proteolytically modified material. Model-building studies by Blundell et al. (1983) predict that the N-terminal peptide is exposed, as would be expected if it can be removed by proteinases. Further evidence for proteolysis in the colostrum comes from the existence of aS2-casein fragments in the purified IGF-1.
These were detected as minor contaminants in three samples used for sequence analysis and differed from each other owing to the possession of N-termini at positions 166, 168 and 174 (Brignon et al., 1977) as identified by reference to the NIH/NCI protein database.
We have compared the pool-3 material (Table 1) with purified human IGF-1, human IGF-2 and rat IGF-2 in a number of radioreceptor assays, radioimmunoassays and biological-responsiveness tests and report these results in the accompanying papers Ballard et al., 1986) . In each test the bovine IGF-1 is much more similar in reactivity to human IGF-1 than to either of the IGF-2 preparations.
If allowance is made for the purity of pool-3 bovine IGF-1 being 60-70%, an estimate based on the minor contaminants detected by gel-permeation chromatography (Fig. 4) and the aS2-casein fragment identified during sequence analysis, we find that bovine IGF-1 and human IGF-1: (a) have similar reactivity towards the ar.ti-(human IGF-1) monoclonal antibody; (b) have similar reactivity towards type-I IGF receptors, as noted in the human-placental-membrane assay; (c) differ in the polyclonal immunoassay by the human IGF-I being 3-5-fold more potent; (d) differ in the type-2 IGF receptor assays (sheep placental membranes, foetalhuman liver, L6 myoblasts, plasma membranes with IGF-2 as radioligand) by the bovine IGF-I being twice as potent, and (e) differ in ability to evoke biological responses by the bovine IGF-I being somewhat more potent.
The difference in reactivity towards the type-2 IGF receptor could be explained if the bovine IGF contained a small contaminant of IGF-2, but evidence against this has been outlined above. It seems more probable that true differences occur between the two IGF-1 molecules, as also is indicated by the unusually low solubility of the bovine form at neutral or alkaline pH. The extent to which the differences relate to amino acid substitutions at positions beyond those sequenced here or to the deletion of the N-terminal tripeptide must await further study.
The placental-membrane-receptor assay indicated that 2.5 mg ofIGF-1 was loaded on to the first h.p.l.c. column. Even if this represented a quantitative recovery of IGF-1 from colostrum, it reflects a concentration above 1 ,ug/ml in the starting material. In contrast, Baxter et al. (1984) have reported only 20 ng of IGF-1 /ml in day-l human colostrum. The opposite situation applies to epidermal growth factor, which is present in human colostrum at approx. 300 ng/ml (Read et al., 1984; Beardmore et al., 1983 ), but at no more than 5% of this concentration in bovine colostrum (Shing & Klagsbrun, 1984; Read et al., 1984) . Whether the altered pattern of growth-factor content in colostrum reflects species-specific differences in their site of synthesis has not been determined. Further analysis of the spectrum of growth factors in colostrum and milk, together with measurements ofmammary-gland concentration or synthesis of growth factors, can be expected to help resolve the biological importance to the newborn animal of milk-derived IGF, epidermal growth factor or other growth factors.
